Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome

Condition(s) targeted: Netherton Syndrome

Intervention: Elidel (Pimecrolimus) 1% Cream (Drug)

Phase: Phase 1/Phase 2

Status: Completed

Sponsored by: Children's Hospital of Philadelphia

Official(s) and/or principal investigator(s):
Albert C Yan, MD, Principal Investigator, Affiliation: Children's Hospital of Philadelphia

Netherton syndrome is a genetic condition that can result in abnormal skin functioning. People with this condition often have red and scaling skin; sparse or short hair; and problems with absorption of medicines or chemicals that are applied to the skin. If these chemicals are absorbed at a high level, they may cause health problems. Elidel (pimecrolimus) is a new medicine that is available as a cream. It has been shown to help improve the appearance of the skin in patients with another skin condition known as atopic dermatitis, and is approved by the United States (US) Food and Drug Administration for use in children with mild to moderate atopic dermatitis. The purpose of this study is to determine if Elidel is safe, to see whether the medication is absorbed through the skin, and to see if side effects are associated with its use in children with Netherton syndrome.

Official title: Exploratory Safety and Systemic Absorption of Elidel (Pimecrolimus) 1% Cream for the Treatment of Netherton Syndrome

Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Primary outcome:

Blood concentration of pimecrolimus

Eczema Area and Severity Index (EASI)

Netherton Area and Severity Assessment (NASA)

Investigator's Global Evaluation of Disease (IGED)

Pruritus Severity Assessment

Transepidermal water loss

Secondary outcome:

Complete blood count with differential

Blood electrolytes and fasting glucose

Blood urea nitrogen and creatinine

Liver function tests

Detailed description: Patients with Netherton syndrome, a rare genodermatosis, manifest a chronic, eczematous dermatitis with erythema and scaling that is often recalcitrant to conventional therapy with emollients and topical corticosteroids. These patients display an altered epidermal barrier with increased permeability to topical agents and are therefore susceptible to evaporative transepidermal water loss and infection. Topical therapy with the calcineurin inhibitors tacrolimus and pimecrolimus has been demonstrated to improve the skin integrity and the quality of life of patients with several chronic dermatoses, including atopic dermatitis. As a result of the underlying skin barrier dysfunction, however, the possibility of significant systemic absorption and resultant side effects is a concern when these agents are used in patients with Netherton syndrome. Experience with topical tacrolimus 0. 1% ointment for patients with Netherton syndrome has demonstrated both marked efficacy as well as significant systemic absorption of the drug in this patient population. Use of topical pimecrolimus in patients with Netherton syndrome has not been reported to date. Investigation of the extent of systemic absorption and side effects will help to define the safety and efficacy profile of topical pimecrolimus in patients with Netherton syndrome.

Minimum age: 2 Years. Maximum age: 18 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Clinical diagnosis of Netherton syndrome

- Normal laboratory values within 3 months prior to enrollment

- Signed written informed consent

- Willingness and ability to comply with the study requirements

- For women of childbearing age, negative urine pregnancy test at enrollment and then

monthly thereafter; women of childbearing age who are not abstinent must use contraception.

Exclusion Criteria:

- Clinically significant physical examination or laboratory abnormalities

- Clinical evidence of liver disease or liver injury as documented by abnormal liver

function tests

- Symptoms of a significant acute illness in the 30 week period preceding the start of

treatment

- Patients with known serious adverse reactions or hypersensitivity to macrolides or

calcineurin inhibitors or with known hypersensitivity to any of the ingredients of the study medication or history of adverse reactions to the anesthetic product used for blood draws

- Topical tacrolimus or Elidel within 2 weeks prior to dosing

- Systemic steroid, systemic tacrolimus, or any immunosuppressant within 1 month prior

to dosing

- Phototherapy within 1 month prior to dosing

- Use of inhibitors of CYP3A4 iso-enzyme within 2 weeks prior to dosing

- Topical steroids or other topical therapy (except tacrolimus) may be used up to the

day of 1st application of Elidel; however, treatment must be discontinued during the treatment period. Topical treatment of corticosteroids may resume immediately after the treatment period or in case an alert value has been exceeded and the Elidel treatment will be continued only on the face and neck.

- Participation in any clinical trials within 2 months prior to dosing

- History or clinical evidence of cardiovascular, respiratory, renal, hepatic,

gastrointestinal, hematologic, neurologic disease, or any disease other than Netherton syndrome, that may put the subject at undue risk. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs.

- History of presence of malignancy or lymphoproliferative disease

- Presence of any viral or fungal or untreated bacterial skin infection

- Known HIV positivity or active hepatitis B or C

- History of immunocompromise

- No vaccines containing live viruses are to be administered during the study period.

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, United States

Children's Hospital of Philadelphia

Foundation for Ichthyosis and Related Skin Types

Starting date: September 2005
Ending date: March 2008
Last updated: May 9, 2008